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Introduction
    Many studies have suggested that diabetes or hyperglycemia affects the sensitivity of
laboratory animals to various pharmacological agents. Several reports have demonstrated
an increased sensitivity of hyperglycemic or diabetic animals to barbituratesis2•28•52•5S' and
a decreased sensitivity to d-amphetamineii,33-36), P-chloroamphetamine32) and carbon tetra-
chloridei3•'`'. The first definitive evidence that mice and rats with streptozotocin-induced
diabetes and spontaneously diabetic mice ard significantly less sensitive than non-diabetic
mice to the antinociceptive effect of morphine was obtained by Simon and Dewey`8' and
Simon et al`9). However, there is little information available regarding the mechanism
responsible for these changes in the potency of morphine. This chapter provides an
overview of our current understanding of the effects of streptozotocin-induced diabetes on
opioid-induced antinociception. The mechanisms of the changes in the potency of morphine-
induced antinociception are also discussed,
1. Selective pt-, O- and s-Agonist-induced Antinociception in Diabetic mice
    In mice, it has been shown that streptozotocin-induced diabetes selectively alters the
nociceptive threshold as determined by the application of a noxious mechanical stimulus
(tail-pinch test), but not as determined by the application of a noxious thermal stimulus
(tail-fiicktest) (Table1)ie'. However, mice which have been rendered diabetic for 2 weeks
show a lower sensitivity to systemic administration of morphine than non-diabetic mice, as
determined by both the tail-pinch and tail-flick responses (Figure 1). It seems likely that
the reduction in the antinociceptive potency of morphine in diabetic mice is not caused by
a reduction in the nociceptive perception thresholdiT'.
   The antinociceptive effect of intracerebroventricularly administered morphine is also
smaller in diabetic mice than in non-diabetic micei". This attenuation cannot be explained
by pharmacokinetic considerations since in this study the morphine was administered directly
into the brain. Likewise, the attenuation of antinociceptive effect is probably not due to
any change in the metabolism of morphine since the same results were obtained with [D-Ala2,
N-MePhe` Gly-o15] enkephalin (DAMGO), a selective pt-opioid agonist (Table 2).
    On the other hand, there is no difference between the responses of non-diabetic mice
and diabetic mice to intracerebroventricular and systemic administration of U-50, 488H, a
selective rc-opioid agonist (Table 2). In contrast, diabetic mice had a significantly increased
sensitivity to intracerebroventricular [D-Pen2•5] enkephalin (DPDPE), a selective b-opioid
agonist, as compared with non-diabetic mice (Table 2). Therefore, these results taken
together suggest that diabetic mice are selectively hyporesponsive to antinociception medi-
ated by supraspinal pt-opioid receptors, but are normally responsive to activation of rc-opioid
receptors. Furthermore, the deficient in the functioning of the pt-opioid receptors in diabetic
mice results in the activation of a `backup' antinociceptive system which is midiated by
6-opioid receptors.
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Table 1. Latency of the responses in the tail-pinch and
   streptozotocin-induced diabetes.
tail-fiick test in mice with
Tail-pinch Latency Tail-flick Latency
Non-diabetes
Diabetes
2.3Å}O.3sec (23)
1.4Å}O.2 sec* (26)
7.1Å}O.3 sec (21)
7.0Å}O.3 sec (22)
Fig. 1.
Data are shown as mean Å} S.E. with number of
Significant difference (PÅqO.05) from non-diabetes
asterisk.
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mice in parentheses.
value is indicated by
The effects of streptozotocin-induced diabetes (dotted
antinociceptive effect of morphine (10mg/kg, s.c.) as
pinch test (A), and on the antinociceptive effect of
determined by the tail-flick test (B). The ordinate
the maxlmum possible effect (%MPE). Data are shown
the results from 10 animals. Asterisk
from the yalue of non•diabetes (open column).
           column) in mice on the
           determined by the tail-
         morphine (5 mg/kg, s.c.) as
         represents the percentage of
              as the mean Å} S.E. of
indicases a significant difference (PÅqO.05)
                (Data from Ref. 17)
   There is considerable evidence to indicate that agonists of pt-, 6- and rc-opioid receptors
can produce antinociception after direct intracerebroventricular administration or after in-
trathecal administration into the subarachnoid space of the spinal cord9,46•4T•5i•e4•7`). One of
the most important aims of this chapter is to provide evidence in support of the idea that
a spinal andlor a supraspinal site contributes to the reduction in the antinociceptive potency
of pt-opioid agonists in diabetic animals. Our recent studies clearly showed that the anti-
nociceptive effects of intracerebroventricular administration of pt-opioid agonists, such as
morphine and DAMGO, were significantly less in diabetic mice than in non-diabetic micei7',
whereas there were no significant differences between the antinociceptive potencies of these
p-opioid agonists between diabetic and non-diabetic mice when they were administered
intrathecally (Table 2). These results confirm that the reduction in the antinoeiceptive
potency of pt-opioid agonists in diabetic mice is due to the dysfunction of supraspinal
mediation of opioid antinociception. Unlike the effect produced by U-50, 488H administered
either intracerebroventricularly or systemically, the antinociceptive potency of U-50, 488H
-
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 x-opioid
% of the maxlmumpossible effect
Non-diabetes (n) Diabetes (n)
Jntracerebroventric"larly
 DAMGO (O.5 ptg)
 DPDPE (5 ptg)
 U-50, 488H (10 ptg)
Intrathecally
42.7+ 5
55.6+18
45,4+10
4% (6)
3% (6)
4% (6)
 9.5Å}
96.7+
46.0Å}
1.2% (6) *
3.3% (6) *
6.2% (6)
             DAMGO (10 ng) 59.2Å}12.89, (6) 65 3Å} 12.2% (6)
             DPDPE (5 ptg) 34.4Å} 6.5% (6) 83.7Å}10.0% (6)"
             U-50, 488H (50 tig) 97.6Å} 2.4%o (6) 46.3Å}14,5% (6)"
          The antinociceptive effect was determined by the tail-flick test 30 min after
          intracerebroventricular or 10 min after intrathecal administration of each
          drug. Data are shown as the rnean Å} S.E. The intensity of a heat lamp
          was set to provide a pre-drug latency time in the tail-flick response of 2-4 sec.
          The cut-off latency was 30sec. Asterisks indicate a significant difference
          (PÅqO.05) from the non-diabetes values.
administered intrathecally is significantly less in diabetic mice than in non-diabetic mice
(Table 2). In contrast to the antinociceptive potency of this rc-opioid agonist, the anti-
nociceptive potency of intrathecally or intracerebroventricularly administered DPDPE, a
6-opioid agonist, is greater in diabetic mice than in non-diabetic mice (Table 2). These
data suggest that at the spinal level, the reduction in rc-opioid receptor-mediated antinocicep-
tion in diabetic mice results in the activation of a 6-opioid receptor-mediated antinociceptive
system.
2. Effect of Diabetes on the Antinociceptive effect of P-endorphin
   Although intracerebroventricular administration of P-endoorphin, an endogenous opioid
peptideiO•3i•5`), produces a marked antinociception in both diabetic and non-diabetic mice,
this effect is greater in diabetic mice than in non-diabetic mice (Table 3). The antinocicep-
tive effects of P-endorphin in both diabetic and non-diabetic mice are significantly antagonized
by systemic administration of naltrindole, a selective 6-opioid receptor antagonist (Table 3).
These findings are consistent with previous suggestions that the antinociceptive effect of
P-endorphin is mediated by stimulation of 6-opioid receptors in the spinal cord5`•55•5'•6T'.
Furthermore, the antinociceptive effect of intracerebroventricularly administered B-endorphin
in diabetic mice is more responsive to naltrindole than that in non-diabetic mice. Indeed,
a low dose of naltrindole (O.1 mglkg), which has no significant effect on the antinociceptive
effect of intracerebroventricularly administered P-endorphin in non-diabetic mice, significant!y
reduces the antinociceptive effect of P-endorphin in diabetic mice (Table 3). Tseng and
coworkers55-57•65) concluded that antinociception induced by intracerebroventricular admin-
istration of P-endorphin is mediated by e-opioid receptors, but not by pt-, a- or rc-opioid
receptors. They also demonstrated that intracerebroventricular administration of P-endorphin
caused the release of immunoreactive Met-enkephalin, which has a high athnity for b-opioid
receptors2e), from the spinal cord67-69). Moreover, the antinociception which was induced
by intracerebroventricular administration of P-endorphin was antagonized by intrathecal
administration of naltrindole5"'. Based on these observations, Suh and Tseng55) proposed
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that supraspinally administered P-endorphin-induced antinociception is mediated by the
stimulation of e-opioid receptors and by the subsequent release of Met-enkephalin and
stimulation of 6-opioid receptors in the spinal cord. Therefore, several mechanisms for
the enhanced P-endorphin-induced antinociception in diabetic mice should be considered:
1) the up-regulation of e-opioid receptors, 2) an increase in the release of Met-enkephalin
in the spinal cord, and 3) the up-regulation of 6-opioid receptors in the spinal cord. As
mentioned above, the antinociceptive potency of intrathecally administered DPDPE, a
selective fi-opioid agonist, is markedly increased in diabetic mice as compared with its
effect in non-diabetic mice. Thus, the enhanced intracerebroventricularly administered
P-endorphin-induced antinociception in diabetic mice may be due to the up-regulation of
O-opioid receptors in the spinal cord. However, it is impossible to exclude the other two
possibilities. Further studies are required to resolve this issue.
   Unlike the effect produced by intracerebroventricularly administered P-endorphin, the
antinociceptive pQtency of intrathecally administered P-endorphin is markedly less in diabetic
mice than in non-diabetic mice (Table 4). In this regard, the antinociceptive potency of
intrathecally administered U-50, 488H, a rc-opioid receptor agonist, is significantly less in
diabetic mice than in non-diabetic mice22'. Since the antinociception induced by intrathecal
     Table 3. Effects of naltrindole (NTI) injected s.c. on EDso values for P-endorphin admin-
             istered i.c.v. for inhibition of the tail-flick response in diabetic and non-
             diabetic mice.
EDsoa values (pg, i.v.c.) for P-endorphin
NTI (mg/kg, s.c.)
Saline O.1 1.0
Non-diabetes
Diabetes
   O.43
(O.29-O.64)b
   O.07d
(o.os-o.Ie)
   O.54
(O.24-1.25)
  O.41c
(O.26-O.64)
   1.12e
(O.88-1.42)
   O.62c
(O.32-1.22)
   aEDso values and its 95% confidence limits were determined using the linear
   regression lines.
   b95% confidence limits.
   CSignificant difference from saline group at PÅqO.05.
   bSignificant difference frorn non-diabetic mice at PÅqO.05.
   (Data from Ref. 22)
Table 4. EDso values for P-endorphin administered i.t. for inhibiton of the tail-flick
        response in diabetic and non-diabetlc mice.
                                        ED50a (ptg, i.t.)
Non-diabetes
Diabetes
  O.58
(O.41-O.82)b
  1.17c
(O.83-1.65)
aEDbo values and its 95% confidence limits were
linear regression lines.
b95% confidence limits.
eSignificant difference from non-diabetic mice at
(Data from Ref. 22)
determined
PÅqO.05.
using the
-
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administration of P-endorphin is antagonized by N- and pt-opioid antagonists, but not by e-
or 6-opioid receptors, Tseng and Collins66' suggested that the antinociception induced by
intrathecal administration of P-endorphin was mediated by the stimulation of rc- and pt-opioid
receptors, but not of e- or 6-opioid receptors, Furthermore, in both diabetic and non-diabetic
mice, the antinociceptive effect of intrathecal administration of P-endorphin is antagonized
by nor-binaltorphimine, a selective rc-opioid receptor antagonist22'. These data suggest that
the down-regulation of rc-opioid receptors in the spinal cord may account for the significant
reduction in the antinociceptive potency of intrathecally administered P-endorphin in diabetic
mice, as compared with its effect in non-diabetic mice.
3. Role of Spleen Products in the Deficient pt-opioid Agonist-indueed Antinociception
   in Diabetie mice
   The selective deficiency in pt-opioid receptor-mediated antinociception displayed by
diabetic mice bears a remarkable resemblance to that displayed by mice of the beige-J
strain (C57BL!6J-bgJlbgJ)37'. It has been reported that beige-J mice are less responsive than
their normal littermates to the antinociceptive effects of centrally administered pt-opioid
agonists, such as morphine and DAMGO, but are normally responsive to the a-opioid
agonist [D-Pen2, L-Pen5] enkephalin37'. The antinociceptive defect of beige-J mice can be
reverse if the mice are splenectomized`3). Furthermore, Raffa et al.`3) reported that some
circulating factor(s) that originate(s) in mononuclear spleen cells may contribute to the
demonstrated poor antinociceptive response of beige-J mice to pt-opioid agonists. The fact
that the antinociceptive defect of beige-J mice can be reversed suggests that their insensi-
tivity to pt-opioid agonists is not due to a genetic inability to synthesize functional pt-opioid
receptors, but rather that the antinociceptive response is somehow suppressed by an en-
Fig.
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aE 50
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o
                  Sham Splx                               Splx
            Sham
                 --
                 Non-diabeticmice Diabetic mice
2, Effect of splenectomy on the antinociception produced by intracerebro-
   venticular (i.c.v.) administration of DAMGO (O.5ptg) in diabetic and
   non-diabetic mice. The mice were tested 7 days after splenectomy
   (Splx) or sham operation (Sham). The ordinate represents the % of
   the rnaximum possible effect (%MPE). Each column represents the
   mean Å} S.E. of the results from 6 animals. Asterisk indicates a
   significant difference (PÅqO.05) frorn the splenectomized diabetic mice.
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        Fig. 3. Effects of spleen mononuclear cells from diabetic mice on the antino-
               ciception produced by intracerebroventricular (i.c.v.) administration of
               DAMGO (O.5rtg) in naive mice. The naive mice were injected with
               vehicle or with spleen mononuclear cells from non-diabetic (SpC-N) or
               diabetic (SpC-D) mice, The mice were tested 7 days after injection of
               the spleen cells. The ordinate represents the % of the maximum
               possible effect (%MPE). Each column represents the mean Å} S.E. of
               the results from 6 animals. Asterisk indicates a significant difference
               (PÅqO.05) from both the vehicle-treated and SpC-N-treated group.
dogenous substance(s). It is possible that the abnormally low eMcacy of pt-opioid agonists
in diabetic mice may be due to some factor(s) derived from spleen cells, as in beige-J mice.
In this regard, recent studies'8•23) have demonstrated that: 1) splenectomized diabetic mice
have a significantly higher sensitivity to y-opioid agonist-induced antinociception than
untreated or sham-operated diabetic mice (Figure 2); and 2) naive mice injected with
mononuclear spleen cells or supernatant of spleen cell homogenate from diabetic mice
exhibit a lower sensitivity to pt-opioid agonist-induced antinociception than vehicle-injected
naive mice (Figure 3.). These results suggest that some factor(s) derived from spleen cells
may contribute to the reduction in the effects of pt-opioid agonists in diabetic mice.
   It is currently unclear whether the defective response of diabetic mice to pt-opioid
agonists is related to an effect of the spleen-derived factor(s) on the characteristics of
ge-opioid receptors, such as their population or their aMnity, or to some other effects on
the overall receptor-effector sequence. Since the aMnity and population of pt-opioid receptors
in beige-J mice are not significantly different from those of their littermates"', Raffa et
al.43•4eV' postulated that the abnormally low sensitivity of beige-J mice to pt-opioid agonists
is not due to an abnormally small population of pt-opioid receptors in the brain but either
to a defect in the pt-opioid receptor-effector coupling mechanisms, or to some factor(s) that
inhibits the binding of pt-opioid agonists to receptors. Brase et al.S) reported that there
were no differences between the high-aMnity binding of [3H] naloxone in spontaneously
diabetic C57BLIKsJ (dbldb) mice and in corresponding controls. Furthermore, streptozotocin-
induced diabetes also has no effect on the high-aMnity binding of [3H] naloxone8'. Therefore,
these results indicate that the population and the athnity of pt-opioid receptors in diabetic
mice are not different from those in naive mice. Thus, the factor(s) derived from the
spleen cells of diabetic mice reduce(s) the antinociception mediated by pt-opioid agonists
-
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either by modifying the pt-opioid receptor-effector coupling mechanisms or by modifying
the binding of pt-opioid agonists to receptors, as do the spleen-derived factors(s) from
beige-J mice.
   We recently demonstrated that when diabetic mice were chronically pretreated with
cyclosporine, a potent immunosuppressive agent5-T,i5', sensitivity to the antinociceptive
effect of morphine in these mice returned to levels observed in non-diabetic mice23).
Moreover, naive mice which had been injected with supernatant of spleen cell homogenate
from diabetic mice exhibited a lower sensitivity to morphine-induced antinociception than
vehicle-treated naive mice. However, naive mice that had been injected with supernatant
of spleen cell homogenate from diabetic mice which had been chronically pretreated with
cyclosporine showed a normal response to the activation of pt-opioid receptors by morphine.
These results suggest that the abnormal antinociceptive effects of /.t-opioid agonists and
the immune responses of diabetic mice may somehow be related.
4. Reduction in Adenosine Triphosphate•sensitive Potassium Channel-mediated Antino-
   ciception in Diabetic mice
   Stimulation of pt- and 6-opioid receptors opens potassium channels in several areas of
the CNSTi•72'. Furthermore, recent reports suggest that antinociception induced by morphine
may be associated with adenosine triphosphate (ATP)-sensitive potassium channels`i•'3'. We
recently demonstrated that cromakalim, a potassium channel activator, produces antino-
ciception which is sensitive to glibenclamide, a selective ATP-sensitive potassium channel
blocker`O'. Thus, we hypothesized that the abnormally low eMcacy of "-opioid agonists in
diabetic mice may be due to functional changes in ATP-sensitive potassium channels.
   To test this hypothesis, we examined the antinociceptive effect of intracerebroventricular
administration of cromakalim in diabetic micee`'. The antinociceptive effect of cromakalim
in non-diabetic mice was antagonized by glibenclamide, while tetraethylammonium, a
compound thought to act on other types of potassium channels, had no significant effect.
In diabetic mice, the antinociceptive effect of cromakalim was also antagonized by gliben-
clamide, but not by tetraethylammonium. However, cromakalim-induced antinociception
was significantly less in diabetic mice than in non-diabetic mice. These results clearly
demonstrate that the activity of supraspinal ATP-sensitive potassium channels is less in
diabetic mice than that in non-diabetic mice. These results also indicate that dysfunction
of ATP-sensitive potassium channels may contribute to the reduction in pt-opioid agonist-
mediated antinociception in diabetic mice.
   ATP-sensitive potassium channels are indirectly blocked by glucose, an ATP-generating
substrate3'. On the other hand, 2-deoxyglucose may activate these channels by reducing
the intracellular concentration of ATP3), In this regard, Singh et al.50' proposed that the
antagonism of morphine-induced antinociception produced by glucose and the increase in
this antinociception induced by 2-deoxyglucose may be due to the different effects of these
drugs on the intrace!lular concentration of ATP. Therefore, it is possible that higher
serum glucose levels may be responsible for the decreased activity of ATP-sensitive potas-
sium channels in diabetic mice. However, when insulin was administered to diabetic mice
to normalized serum glucose levels, sensitivity to cromakalim-induced antinociception was
still significantly lower than that in non-diabetic mice2`'. Furthermore, the antinociceptive
potency of DAMGO in insulin-treated diabetic mice was also still significantly lower than
that in non-diabetic mice2b'. Therefore, the decreased activity of ATP-sensitive potassium
channels, like the potencies pt-opioid agonists, may not be due to the higher serum glucose
-
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4. Effects of glibenclamide and tetraethylammnonium on antinociception produced
   by intracerebroventricular (i.c.v.) administration of cromakalim in non-diabetic
   and diabetic mice. Antinociception was tested 30 min after i.c.v. cromakalim
   (1 or 3 ptg) treatment. Glibenclamide (GLI, 30 ptg) or tetraethylammonium (TEA,
   30 rtg) was injected i.c.v. 10 rnin before cromakalim administration. Each column
   represents the mean Å} S.E. of the results from 6 animals. Asterisk indicates a
   significant difference (PÅqO.05) from cromakalim + vehicle (open column).
   (Data from Ref. 24)
Table 5. Effects of i.c.v. administration of cromakalim on the tail-fiick response in both
non-diabetic and diabetic mice.
Treatment %MPE
Non-diabetic mice
Vehicle
Cromakalim (O.3 pg, i.c.v.)
Cromakalim (1.0 pg, i.c.v.)
 2.4Å} 1.3%(5)
29.5Å} 6.0% (5)*
74.4Å}10,3%(5)*
Diabetic mice
Vehicle
Cromakalim (1.0 xig, i.c.v.)
Cromakalim (3.0pg, i.c.v.)
 2.9Å} 1.7%(6)
11.9Å} 3.5% (6)*i**
20.7Å} 6.3%(6)*J**
Antinociception was tested 30 min after i,c.v. cromakalim treatment.
The values represent the mean Å} S.E. of the percent of the maximum
possible effect (%MPE). 'indicates a significant difference (PÅqO.05) from
respective vehicle-treated group. **indicates a significant difference (PÅq
O.05) from the value of cromakatim (1 gg, i.c.v.)-treated non-nibetic mice.
(Data from Ref. 24)
levels associated with diabetes. In this regard, we also suggested that some factor(s) derived
from spleen cells may play an important role in the reduction of pt-opioid agonist-mediated
antinociception in diabetic mice'8). These factor(s) may contribute to the dysfunction of
ATP-sensitive potassium channels in diabetes.
-
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   The antinociception produced by the selective 6-opioid agonist DPDPE in non-diabetic
mice is sensitive to glibenclamide, but not to tetraethylammonium2`'. This result confirms
the previous suggestion that this type of 6-opioid receptor is linked to ATP-sensitive
potassium channels'3'. Thus, we should expect diabetic animals to be significantly less
sensitive to the antinociceptive effect of DPDPE than non-diabetic mice. Although diabetic
mice are hyporesponsive to antnociception mediated by pt-opioid receptors, they are hyper-
responsive to activation of 6-opioid receptors (Table 2). Furthermore, the antinociceptive
effect of DPDPE in diabetic mice is insensitive to glibenclamide and tetraethylammonium2`'.
Therefore, while the details of the mechanisms are presently unknown, DPDPE-induced
antinociception in diabetic mice may be independent of potassium channels.
5. Naloxone-induced Antinocieeption in Diabetic mice
   Several investigators have demonstrated that repeated treatment with naloxone produces
what is known as paradoxical antinociceptioni2•58•59'. Chronic exposure to opioid antagonists,
such as naloxone and naltrexone, has been shown to up-regulate brain opioid binding sites
and to increase the antinociceptive action of morphine`,29,38,39,6i,62,T5-7T). Thus, it has been
suggested that paradoxical antinociception may be attributable to up-regulation of pt- and
6-opioid receptors. On the other hand, Greeley et al.i2' hypothesized that blockade of
endogenous opiates by the antagonist results in activation of a normally redundant `backup'
antinociceptive system. Mice with diabetes are selectively hyporesponsive to antinociception
mediated by supraspinal pt-opioid receptorsi7'. In other words, selective blockade of p-opioid
receptors develops in the brains of diabetic mice. Thus, it seems possible that activation
of a `backup' antinociceptive system may occur in diabetic mice. In fact, we have observed
that acute treatment with naloxone produces a marked antinociception in diabetic micei9'.
This effect is dose-related and is sensitive to naltrindole, a 6-opioid receptor antagonist.
These findings indicate that naloxone-induced paradoxical antinociception in diabetic mice
may be mediated by S-opioid receptors.
   We found that the extent of swimming stress-induced antinociception in diabetic mice
was significantly greater than that in non-diabetic mice20'. It has been recognized that
stress-induced antinociception is mediated by complex endogenous antinociceptive systems,
which involve both opioid and non-opioid mechanisms27,30•`2,6e,63,'O). Indeed, stress-induced
antinociception is blocked by naltrindole, a selective antagonist of 6-opioid receptors, but
not by pretreatment with P-funaltrexamine, an irreversible and selective antagonist of f.t-
opioid receptors20'. Thus, it seems likely that the deficient functioning of y-opioid receptors
caused by diabetes results in activation of an endogenous antinociceptive system which is
mediated mainly by 5-opioid receptors. This hypothesis is strongly supported by the
observation that acutely administered naloxone has a potent antinociceptive effect on
diabetic mice'9'. Naloxone-induced antinociception in diabetic mice is blocked by an an-
tagonist of 6-opioid receptors, naltrindole, but not by B-funaltrexaminei9'. Furthermore,
the antinociception induced by DPDPE, but not that induced by DAMGO or U-50, 488H,
is significantly greater in diabetic mice than in non-diabetic mice (Table 2). Moreover,
both the naloxone-induced paradoxical antinociception and the selective hyperresponsiveness
to antinociception mediated by a 6-opioid agonist in diabetic mice are significantly attenuated
by chronic treatment with naloxone2i'. These findings also support the suggestion that
dysfunction of ft-opioid receptors in diabetic mice results in activation of a `backup' an-
tinociceptive system which is mediated by fi-opioid receptors.
-
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Summary
   It is now clear that diabetic mice are selectively hyporesponsive to antinociception
mediated by supraspinal pt-opioid receptors. In contrast, at the spinal level, diabetic mice
are selectively hyporesponsive to antinociception mediated by rc-opioid receptors. Further-
more, the deficient functioning of pt-opioid receptors at the supraspinal level and rc-opioid
receptors at the spinal level in diabetic mice results in the activation of a b-opioid receptor-
mediated `backup' antinociceptive system at both the supra$pinal and spinal levels.
   The dysfunction of ATP-sensitive potassium channels may contribute to the reduction
in y-opioid agonist-mediated antinociception in diabetic mice. Furthermore, some factor(s)
derived from spleen cells may contribute to the dysfunction of ATP-sensitive potassium
channels in diabetes (Figure 5). Moreover, the abnormal antinociceptive effects of p-opioid
agonists and the immune responses of diabetic mice may somehow be related.
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Fig. 5. Schematic drawing of the possible target site or mechanism for the reduction
       in xt-opioid agonist-mediated antinociception in diabetic mice, Åq : inhibition.
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